We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Werfen Unveils Next Generation Hemostasis Testing Systems

By LabMedica International staff writers
Posted on 30 Jul 2025

Werfen (Barcelona, Spain) is unveiling the next generation of market-leading ACL TOP hemostasis testing systems at the ADLM Annual Meeting 2025, reinforcing the company’s commitment to innovation in specialized diagnostics. More...

Werfen also has announced the expansion of its award-winning Gem Premier 7000 with iQM3 to Europe, following its strong clinical adoption in North America.

Werfen had recently announced the commercialization of ACL TOP Family 70 Series hemostasis testing systems in North America, following 510(k) clearance by the US Food and Drug Administration and licensure by Health Canada. Building upon the company’s established legacy of quality and innovation in hemostasis testing, the ACL TOP Family 70 series hemostasis testing systems optimize workflow with a powerful combination of quality and efficiency, and connectivity across an entire laboratory network. To streamline and optimize workflow, ACL TOP Family 70 Series systems offer centralized QC and automated performance verification management. When connected to HemoHub Intelligent Data Manager, synergistic integration allows uniform application of a laboratory’s Quality Management System across multiple instruments and sites, from one centralized location; transcription errors are eliminated, and report generation and storage are automated. Performance verification studies that previously involved several manual processes are reduced to two automated steps, saving significant staff time, improving quality, and reducing costs.

At ADLM 2025, Werfen has announced the expanded commercialization for the GEM Premier 7000 with iQM3, following its early success in North America. Building on strong clinical adoption and recognition in the United States, the system is now available in Europe. The GEM Premier 7000 is the first blood gas testing system to integrate hemolysis detection at the point of care, addressing the most common preanalytical error in blood gas testing. The system earned five prestigious industry awards, including the 2025 Edison Award and Premier Inc. Supplier Innovation Award, for its groundbreaking integration of hemolysis detection at the point of care. These honors highlight its innovation, quality, and positive impact on clinical workflows and patient care.

Related Links:
Werfen


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.